Business Context and Reporting Period
This Form 8-K filing by Revelation Biosciences, Inc. (REVB) reports on the results of the Annual Meeting of Stockholders held on May 15, 2024. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
A quorum was established with 614,695 shares present, representing greater than one-third of the 1,632,935 shares entitled to vote. Stockholders approved three key proposals:
- Proposal 1 (Election of Directors): Stockholders elected James Rolke and Jess Roper as Class B directors to serve until the 2027 Annual Meeting.
- James Rolke: 122,822 For, 23,715 Against, 6,620 Abstain.
- Jess Roper: 122,543 For, 27,978 Against, 2,636 Abstain.
- There were 461,538 broker non-votes.
- Proposal 2 (Equity Incentive Plan Amendment): Stockholders approved increasing the shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294.
- Votes: 107,447 For, 42,981 Against, 2,729 Abstain.
- There were 461,538 broker non-votes.
- Proposal 3 (Ratification of Auditor): Stockholders ratified Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2024.
- Votes: 595,879 For, 18,558 Against, 258 Abstain.
- There were no broker non-votes.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly details the submission of matters to a vote of security holders.
Important Facts for Investors to Verify
- Verify the impact of the increased share reserve (from 21,623 to 163,294) on potential future dilution.
- Review the full Proxy Statement referenced in the filing for detailed biographies of the newly elected directors and the specific terms of the Equity Incentive Plan amendment.
- Confirm the company's current cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K does not provide financial status.